Shopping Cart
- Remove All
- Your shopping cart is currently empty
VGX-1027 (GIT 27) is an isoxazole compound with various immunomodulatory properties.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $42 | In Stock | |
10 mg | $68 | In Stock | |
25 mg | $142 | In Stock | |
50 mg | $229 | In Stock | |
100 mg | $367 | In Stock | |
1 mL x 10 mM (in DMSO) | $46 | In Stock |
Description | VGX-1027 (GIT 27) is an isoxazole compound with various immunomodulatory properties. |
In vitro | VGX-1027 enhances survival rates and ameliorates clinical and histopathological signs in the NZB/NZW F1 model of systemic lupus erythematosus, thereby improving disease progression. It prevents the spontaneous development of Type 1 diabetes in NOD mice and counters the acceleration of diabetes induced either by cyclophosphamide assault or by the adoptive transfer of diabetogenic spleen cells in NOD mice. Furthermore, VGX-1027 reduces clinical symptoms of diabetes induced by MLD-STZ and inhibits pathological histological changes in the pancreas. |
In vivo | VGX-1027 exhibits inhibitory effects on the proliferation of gut bacterial antigen-reactive CD4+ CD25- T cells in vitro. It significantly suppresses the accumulation of TNF-α and nitrites induced by IL-1β/IFN-γ, and notably enhances cell survival by interfering with the toxic effects of cytokines. |
Alias | VGX1027, VGX 1027, GIT 27 |
Molecular Weight | 205.21 |
Formula | C11H11NO3 |
Cas No. | 6501-72-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 20.5 mg/mL (100 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.